Boston Celtics Kemba Walker will miss time after stem cell injection in left knee, will be re-evaluated in J – MassLive.com

Boston Celtics guard Kemba Walker will miss time at the start of the season after receiving a stem-cell injection in his left knee, the team announced Tuesday morning.

Per the Celtics, Walker consulted with multiple specialists before settling on a treatment in early October. His timeline for a return was 12 weeks, and he will be re-evaluated in early January. The NBA season is scheduled to open on Dec. 22, so Walker will miss time and then could be limited afterward as the Celtics try to tend to his knee as best they can.

Walker struggled with knee issues all year, playing in just 56 of Bostons regular-season games. He appeared limited at times when the season resumed in the Disney World bubble as well, despite a four-month layoff.

Walker, who is 30, signed a four-year, $140 million contract with the Celtics in 2019.

Per the Celtics, second-year wing Romeo Langford will also miss time. He had a procedure to repair a torn scapholunate ligament in his right wrist in September and was expected to miss four-to-five months. Per the Celtics, his recovery is proceeding on schedule.

Tristan Thompson also suffered a minor hamstring strain and will for the first week of training camp.

Related content

Boston Celtics announce official signings of Tristan Thompson, Jeff Teague

Boston Celtics rumors: Evan Turner will join team on the bench as assistant coach (report)

Gordon Hayward trade: Who Boston Celtics can target, what a traded player exception is, & how to use it

Visit link:
Boston Celtics Kemba Walker will miss time after stem cell injection in left knee, will be re-evaluated in J - MassLive.com

Stem cell therapy in coronavirus disease 2019: current evidence and future potential – DocWire News

This article was originally published here

Cytotherapy. 2020 Nov 9:S1465-3249(20)30932-4. doi: 10.1016/j.jcyt.2020.11.001. Online ahead of print.

ABSTRACT

The end of 2019 saw the beginning of the coronavirus disease 2019 (COVID-19) pandemic that soared in 2020, affecting 215 countries worldwide, with no signs of abating. In an effort to contain the spread of the disease and treat the infected, researchers are racing against several odds to find an effective solution. The unavailability of timely and affordable or definitive treatment has caused significant morbidity and mortality. Acute respiratory distress syndrome (ARDS) caused by an unregulated host inflammatory response toward the viral infection, followed by multi-organ dysfunction or failure, is one of the primary causes of death in severe cases of COVID-19 infection. Currently, empirical management of respiratory and hematological manifestations along with anti-viral agents is being used to treat the infection. The quest is on for both a vaccine and a more definitive management protocol to curtail the spread. Researchers and clinicians are also exploring the possibility of using cell therapy for severe cases of COVID-19 with ARDS. Mesenchymal stromal cells are known to have immunomodulatory properties and have previously been used to treat viral infections. This review explores the potential of mesenchymal stromal cells as cell therapy for ARDS.

PMID:33257213 | DOI:10.1016/j.jcyt.2020.11.001

See the rest here:
Stem cell therapy in coronavirus disease 2019: current evidence and future potential - DocWire News

Hematologist Discusses the Impact a Myeloma CAR T-Cell Approval Would Have on the Treatment Landscape – DocWire News

Ankit Kansagra, MD, an assistant professor in theDepartment of Internal Medicineat UT Southwestern Medical Center and assistant director of theOutpatient Stem Cell Transplant Program, discusses chimeric antigen receptor T-cell agents in the pipeline for multiple myeloma (MM) and how these therapies may impact the treatment landscape pending future approvals.

In part two of this interview with Dr. Kansagra, available December X, he discusses potential new combination therapy options for MM.

DocWire News: Dr. Kansagra, can you discuss some of the CAR T-cell therapies in development for multiple myeloma, including their targets, clinical trial data that weve seen, and your expectations for any future FDA approvals?

Dr. Kansagra: In multiple myeloma, a few of the CAR T-cell therapy targets, which in the most developments, have been the BCMA-targeted CAR T-cell therapies. Those have been most exciting because they have made it to the phase I to phase II trials, especially the registrational studies from Celgene or Bluebird, BMS, the bb2121 compound or the Janssen compound 4538, being farthest out in the clinical development for CAR T-cell therapy. There are certainly a few other CAR T-cell therapies for multiple myeloma, which have grown, and theyre probably in the earlier development of therapy. An example being the CD38 CAR T-cell therapy, the SLAMF CAR T-cell therapy, and GPR5CD CAR T-cell therapy. Those are the three different targets which are being evaluated as T-cell targets.

DocWire News: How do you see the approval of these CAR T-cell therapy impacting the treatment landscape for multiple myeloma?

Dr. Kansagra: I think its going to be a huge improvement in our momentum of our treatment options. We have already seen cell therapy in myeloma have impressive results in terms of the response rates. I think the first important step is you have these patients who have got six or seven different lines of treatment, and now they are getting a novel product or a novel mechanism of action and also novel target and seeing an impressive response rate. That was amazing. Thats step number one.

Step number two is, as we have got further into the clinical development of CAR T-cell therapy, we have seen the safety of these products because that is extremely important that our products are safer.

Then the third thing which we have seen is that long-term follow-ups are not there, but what we have started seeing is that our responses, which could last up to a year or a year and a half for the population, where we would have usually seen maybe barely a response in a matter of months.

I think those are exciting times for our patients with multiple myeloma, where they have failed a lot of therapies. I think the more exciting times are going to come when we will start seeing these CAR T-cell therapies, potentially even in earlier lines of treatment options, where they could use maybe as a second-line treatment or as a first-line treatment after stem cell transplant or in lieu of stem cell transplant, maybe we can have deeper and longer remission rates.

DocWire News: With some of these agents potentially coming to market, do you foresee any challenges, either associated with adverse events or the ability to make these treatments widely available to patients?

Dr. Kansagra: Access to care is certainly near and dear to me, and thinking about those challenges is extremely, extremely important. I think were going to probably face challenges in a lot of different ways.

The first thing is, obviously, how can we get our patients to the centers who are giving CAR T-cell therapy? How are we going to bring them? We know from our autologous stem cell transplant over the last three to four decades, that still not every eligible transplant patient is referred to a transplant center, for whatever reasons. There are multiple reasons; there are socioeconomic reasons; there are distance reasons. But a lot of them are fixable reasons. There are some which are unfixable, but there are some fixable. I think the first and the foremost important thing is going to be to get our patients to a place who is delivering CAR T-cell therapy. Thats the challenge number one.

Challenge number two is, once they are in there, making sure that they are able to get that thing. So it means theyre not coming too late in their game, so trying to make sure theyre referred in earlier points, so that processes in place, that insurance approval has got started, if we need to work on the sociodemographic issues, how are they going to stay in a particular area? What is the social help, what is the family help theyre going to need? If they had referred earlier on, thats another, I call it, bottleneck that we need to think of that. Thats where we need to act on it.

The hard thing is obviously the cost. We dont know what is going to be the cost of the myeloma CAR T-cell therapy, or what is the price of those things. We can certainly estimate that its not going to be as cheap given the three CAR-Ts, which are not FDA-approved. I think its going to be expensive. You will have to think of the cost of care model of how we are going to work with this.

Last but not least of the challenges are the CAR-T itself. These are in the logistical challenge bucket. Then there are the challenges in the CAR-T landscape or the product itself. We still know that these are second-generation CAR T-cell therapies. They dont work for everybody. They have a high response rates, but they dont last that long. We hope to see longer remissions. An example I give, in comparison to large-cell lymphoma, we had 50% of the people who plateaued out, now coming up to about three years. In myeloma, we havent obviously made it to three years since the CAR T-cell therapy have started, but we do worry that there is a tail end of the curve that people are already relapsing to it. Obviously, that goes to the product itself or the construct itself, which needs to be developed in multiple different ways. I think of them as two major challenges ahead of us.

Originally posted here:
Hematologist Discusses the Impact a Myeloma CAR T-Cell Approval Would Have on the Treatment Landscape - DocWire News

Sphingosine 1-phosphate Receptor Modulator ONO-4641 Regulates Trafficking of T Lymphocytes and Hematopoietic Stem Cells and Alleviates Immune-Mediated…

This article was originally published here

J Pharmacol Exp Ther. 2020 Nov 30:JPET-AR-2020-000277. doi: 10.1124/jpet.120.000277. Online ahead of print.

ABSTRACT

ONO-4641 is a second-generation sphingosine 1-phosphate (S1P) receptor modulator that exhibits selectivity for S1P receptors 1 and 5. Treatment with ONO-4641 leads to a reduction in magnetic resonance imaging disease measures in patients with relapsing-remitting multiple sclerosis. The objective of this study was to explore the potential impact of ONO-4641 treatment based on its immunomodulatory effects. Severe aplastic anemia is a bone marrow (BM) failure disease, typically caused by aberrant immune destruction of blood progenitors. Although the T helper type-1-mediated pathology is well described for aplastic anemia, the molecular mechanisms driving disease progression remain undefined. We evaluated the efficacy of ONO-4641 in a mouse model of aplastic anemia. ONO-4641 reduced the severity of BM failure in a dose-dependent manner, resulting in higher blood and BM cell counts. By evaluating the mode of action, we found that ONO-4641 inhibited the infiltration of donor-derived T lymphocytes to the BM. ONO-4641 also induced the accumulation of hematopoietic stem cells in the BM of mice. These observations indicate, for the first time, that S1P receptor modulators demonstrate efficacy in the mouse model of aplastic anemia and suggest that treatment with ONO-4641 might delay the progression of aplastic anemia. Significance Statement ONO-4641 is a second-generation sphingosine 1-phosphate (S1P) receptor modulator selective for S1P receptors 1 and 5. In this study, we demonstrated that ONO-4641 regulates the trafficking of T lymphocytes along with hematopoietic stem and progenitor cells leading to alleviation of pancytopenia and destruction of bone marrow in a bone marrow failure-induced mouse model mimicking human aplastic anemia.

PMID:33257316 | DOI:10.1124/jpet.120.000277

See more here:
Sphingosine 1-phosphate Receptor Modulator ONO-4641 Regulates Trafficking of T Lymphocytes and Hematopoietic Stem Cells and Alleviates Immune-Mediated...

Las Vegas woman allegedly held ‘vampire facial’ parties while posing as nurse – New York Post

An unemployed Las Vegas woman posed as a nurse and gave unlicensed vampire facials to dozens of unwitting clients during illicit parties which left some patients with painful side effects or requiring medical attention, police said.

Maria Sabata Gutierrez, 49, was busted on Nov. 18 as officers executed a search warrant at her home, according to an arrest report obtained by the Las Vegas Review-Journal.

Gutierrez admitted to detectives to administering the treatment designed to re-inject platelet-rich plasma into the skin to activate collagen cells.

She also disclosed selling medications she purchases from Mexico to patients, an arrest report states. She is currently unemployed and does these medical procedures on the side.

Gutierrez, who is identified in the arrest report as Maria DeJesus Gutierrez, told detectives she had been doing the procedures for the past year on roughly 50-60 patients for about $100 a pop, police said.

An investigation was launched by detectives after a woman showed up at a Las Vegas hospital in late September with swelling and pain on her face and bumps in her mouth, police said.

The woman told investigators she got the trendy skin procedure after a recommendation from a friend who attended one of Gutierrezs vampire facial parties illicit get-togethers that took place every other week since as March or April, police said.

After Gutierrez took blood from the customers arms, it was then placed into a machine that separated it before being re-injected into her face, the woman told police.

The treatment at a licensed medical facility typically costs about $1,000, investigators said.

In addition to the vampire facials, [the customer] was also getting a similar procedure with her blood being reinjected into her buttocks, the arrest report states. This procedure has [been] happening weekly and cost $100.

While holding the parties, Gutierrez always wore medical scrubs and a backpack containing a blood centrifuge and other supplies. She told a witness she previously worked for a medical office and did the procedures regularly, but lost her license, police said.

Gutierrez also told a doctor who contacted her after one of her patients went to a hospital that she got her equipment online from Mexico, police said.

She then told the doctor she had been operating out of her trunk, according to the report.

The doctor told Gutierrez to stop performing vampire facials and got in touch with police, prompting undercover detectives to later set up a meeting with her and arranged to get the procedure for $212, police said.

Gutierrez, who is facing charges including furnishing a dangerous drug without a prescription and acting as a medical practitioner without a license, has a preliminary hearing set for March. Her attorney could not be reached for comment Tuesday, the newspaper reported.

Read the rest here:
Las Vegas woman allegedly held 'vampire facial' parties while posing as nurse - New York Post

Travere Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

Topline data from interim 36-week proteinuria endpoint on track for first quarter of 2021 Topline data from interim 36-week proteinuria endpoint on track for first quarter of 2021

Follow this link:
Travere Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

Quotient Limited Announces MosaiQ™ Expanded IH EU Field Trial Performance Data

JERSEY, Channel Islands, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported preliminary EU field trial performance data for its MosaiQ Expanded Immunohematology (IH) Microarray. The data suggest that tests performed with Quotient's Microarray are highly accurate.

See the rest here:
Quotient Limited Announces MosaiQ™ Expanded IH EU Field Trial Performance Data